Drug Profile
Hepatitis B vaccine recombinant SBAS4 - GSK
Alternative Names: Fendrix; HBs AG/AS04; SB M00026; SBAS4Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class DNA vaccines; Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 12 Jul 2005 Corixa Corporation acquired by GlaxoSmithKline
- 27 Oct 2004 The Committee For Medicinal Products for Human Use (CHMP) recommends approval of the vaccine for hepatitis B prevention in the European Union
- 12 May 2003 Preregistration for Hepatitis B prevention in European Union (IM)